

PROJECT DESCRIPTION

1
2
3 **1. Principal Investigator (Co-PI):** Alicia Heapy, Ph.D.
4 Co-PI (off-site): John Piette, PhD – VA Ann Arbor Healthcare System

5
6 **Title: Patient-Centered Pain Care Using Artificial Intelligence and Mobile Health Tools: Phase 2**

7 8 **2. Purpose:**

9 The current study will evaluate a new approach for delivering cognitive behavioral therapy (CBT) pain
10 management that may substantially improve our ability to systematically adapt CBT to patients' unique needs
11 while ensuring that scarce clinician resources focus on patients who need more intensive treatment.
12 Specifically, we will use **Reinforcement Learning (RL)**, a type of **Artificial Intelligence (AI)** to ensure that
13 Veterans with chronic pain receive the intensity and type of therapy they need. Based on patients' daily
14 feedback, AI-CBT will make recommendations to potentially step-up the intensity of each patient's CBT follow-
15 up from automated calls to more engaging live telephone therapy sessions (15 minutes or 45 minutes) as
16 needed. The specific aims of the study are as follows:

- 17 1. Using a randomized non-inferiority design, we will determine whether an AI adaptive program of
18 telephone-based, personalized and stepped pain CBT that includes brief therapy sessions and
19 automated calls as well as standard one hour treatment sessions (AI-CBT) can achieve equal outcomes
20 compared to a standard CBT program of 10 hour-long sessions;
- 21 2. We will use a budget impact analysis to quantify the difference in therapist time associated with AI- CBT
22 relative to standard CBT as well as differences in overall ambulatory and inpatient service use;
- 23 3. We will determine whether AI-CBT results in greater patient satisfaction and engagement, due to its more
24 patient-centered approach that automatically focuses on "what works" for each Veteran.

25 Our *central hypothesis* is that a pain management program that uses AI algorithms and regular feedback
26 collected via IVR about Veterans' physical activity, CBT skill practice, and pain-related physical functioning and
27 that automatically adapts treatment delivery will achieve outcomes that are as good as standard approaches
28 (or even better), but use substantially less clinician time.

29 30 **3. Background:**

31 Musculoskeletal disorders are highly prevalent among VA patients, with chronic back pain the most frequently
32 reported type.^{1,2} Among OEF/OIF Veterans, back pain and other musculoskeletal conditions are the most
33 prevalent of all diagnosed medical and psychiatric conditions.³ VA data suggest an annualized increase in the
34 prevalence of low back pain of 4.8% per year due to factors such as an aging population and increasing
35 prevalence of obesity.^{1,4} Chronic low back pain is associated with work interruption, emotional distress, and
36 risky health behaviors such as substance use.⁵ Emerging evidence suggests that chronic pain compromises
37 successful treatment and management of other chronic conditions.⁶ For all of these reasons, increasing access
38 to effective, convenient treatments for chronic low back pain is a national VA priority.⁷ Cost of treating back
39 pain in VA is \$2.2 billion annually.⁸

40 41 **Cognitive and Behavioral Interventions to Improve Pain Management**

42 CBT is the most widely-accepted evidence-based psychological treatment for chronic pain.⁸ CBT is informed
43 by theory recognizing that patients' beliefs, attitudes and coping styles play central roles in determining their
44 experiences of pain.⁹ CBT is an attractive alternative to pharmacotherapy because impacts on functioning can
45 last long after treatment is discontinued, and CBT does not entail the negative side effects of opioids. The goal
46 of CBT for pain is to assist patients in developing an adaptive problem solving approach to pain management,
47 and CBT targets both reductions in pain symptoms as well as their associated disability and emotional distress.
48 The VA Evidence-Based Psychotherapy (EBP) program uses a CBT for pain that contains 10 hour-long
49 sessions delivered weekly. Sessions provide pain education, teach and encourage the practice of pain self-
50 management skills, and promote productive and pleasurable activity and exercise. Skills address both
51 cognitive processes (e.g., catastrophizing) and behaviors (e.g., relaxation). A meta-analysis found moderate to
52 large effects of CBT in improving pain related outcomes,¹⁰ and a Cochrane systematic review reached nearly
53 identical conclusions.¹¹

55 **Prior Research on Adapting Treatment to Patients' Individual Needs**

56 Another foundational area of research for the proposed study is the theory of tailored health communication, which
57 suggests that patients are more likely to internalize health messages when those messages are relevant to them
58 personally.¹² The state-of-the-science in tailoring uses surveys to identify patients' needs, health beliefs, learning
59 styles, cultural context, and other factors prior to crafting health related messages targeting behavioral changes. The
60 data needed to tailor health messages is substantial, and many patients may not be willing or able to accurately
61 report that information at program outset.¹³ For example, Drs. Kerns and Heapy found that CBT skills training was
62 no more effective when skill presentation was tailored according to what patients thought they wanted before
63 initiating treatment.¹⁴ Also, previous tailoring systems typically have tailored based on static patient traits, rather than
64 on updated information about patients' status or treatment response. In the proposed study, we will tailor Veterans'
65 pain CBT services using IVR reported feedback about their: pain-related physical functioning measured objectively
66 via pedometer step counts, perceived functioning scores, and progress with CBT skill practice. Based on this real-
67 time feedback, AI-CBT will personalize each patient's course of treatment automatically in order to achieve the
68 greatest benefits for the population while using clinical resources as efficiently as possible.

69
70 **Mobile Health (mHealth) Approaches to Self-Management Support**

71 Because mHealth services have low marginal costs, they can cost-effectively reach large numbers of patients
72 between face-to-face encounters to provide self-management support.¹⁵ More than 50 studies have demonstrated
73 that patients can provide reliable and valid information about psychiatric symptoms and substance abuse disorders
74 via IVR and other mobile health technology.¹⁶⁻¹⁹ Trials suggest that mHealth interventions can improve self-
75 management behaviors^{20,21} and may improve outcomes of chronic illness care.²² The benefits of standard CBT
76 diminish after patients discontinue therapy, and maintenance interventions delivered via IVR sustain those
77 improvements in symptoms and self-management skills.^{22,23} Because mHealth services are so promising, VA is
78 making significant investments in development through the national Office of Telehealth.²⁴ Despite their potential,
79 mHealth interventions typically deliver simplistic series of messages based on pre-determined "if-then" rules and
80 deterministic protocols. As a result, mHealth interactions can feel "robotic" to users and many of them may drop out
81 of treatment.²⁵ By way of analogy, no patient would continue to see a physician if that provider failed to adapt their
82 management approach or goals based on the patient's response to prior treatments. We propose a model for taking
83 advantage of the cost and accessibility benefits of mHealth services, while ensuring that these powerful tools are
84 integrated systematically with personal, professional care from trained VA CBT therapists.

85
86
87 **4. Significance:**

88 The proposed team includes VA researchers with a long-history of Veteran-centered health services research on
89 mobile health, and non-VA experts with unique expertise in AI and tailored messaging that can catalyze the
90 development of novel tools for improving chronic pain management. The use of AI to tailor patients' treatment plan
91 is unprecedented in chronic disease management. These approaches have become widely used in other areas
92 (e.g., online advertising) because the powerful AI algorithms can significantly improve the user-centered experience
93 and services' impact on target outcomes. Because this approach can optimize each patient's treatment response
94 with the most efficient use of scarce therapist time, it could dramatically increase the number of Veterans with
95 access to pain CBT given constraints on VHA budgets. Success with this system will provide a foundation for a
96 broader program of research on AI supported interventions to improve chronic illness care for Veterans with high
97 priority chronic conditions such as depression, diabetes, and obesity.

98
99 **5. Research Plan:**


100 **Overview**

101 This will be a randomized non-inferiority study comparing standard CBT for chronic pain to a strategy that uses
102 mobile health technology and artificial intelligence in conjunction with CBT therapists to deliver evidence-
103 based, stepped pain therapy. Patients in both groups will receive CBT delivered via telephone by pain CBT
104 therapists. For patients in the standard CBT group, the therapist will deliver 10, 45 minute-long CBT sessions
105 based on content used throughout VA. Patients randomized to the AI-CBT treatment group, named the
106 *Responsive Efficient Accessible Chronic pain Technology (REACT) program*, will be asked to report their
107 pedometer-measured step-counts, pain-related functioning, and CBT skill practice via five-minute daily IVR
108 calls, and will receive a pre-recorded therapist feedback message at the end of the week. Some of those IVR
109 calls also will include reminders regarding the dates and modalities for upcoming CBT sessions. Based on
110 patients' IVR feedback, AI-CBT will make recommendations to potentially step-up the intensity of each

111 patient's CBT follow-up using more engaging live telephone therapy sessions (15 minutes or 45 minutes).
 112 Based on experience gained from each patient's own history and the overall population of patients, the AI-CBT
 113 engine will seek to optimize the population's total improvement in functioning while maintaining each patient at
 114 the least resource-intensive mode of CBT delivery. Outcomes will be measured via telephone survey at three
 115 and six months post recruitment, and additional data will be collected via clinical records. We will use data from
 116 therapists' activity logs and administrative files to conduct a budget impact analysis. De-identified survey data
 117 will be entered at VA Connecticut or paper copies will be mailed using VA approved carrier and tracking
 118 number to the Ann Arbor VA site for entry by approved staff. Additional data to aid translation of study findings
 119 into practice will be collected via qualitative interviews with CBT therapists/team members, and patients with
 120 various levels of program response.

121 **Conceptual Framework**

122 The intervention we will evaluate is based clinically on widely-adopted and evidence-based models of CBT for
 123 VA pain management (described above),²⁶ and it links those concepts with a strategy for personalized stepped
 124 care using **reinforcement learning (RL)**. RL is a field of artificial intelligence that allows an "intelligent agent"
 125 to learn what treatment choices work best in order to optimize a measurable outcome (termed the system's
 126 "reward"; see Figure 1). The process used to optimize treatment choices in RL mimics the way that humans
 127 learn skills such as riding a bicycle, i.e., through systematic adaptation and generalization accompanied by
 128 targeted trials of new behaviors with measurable outcomes. RL algorithms similar to those we will apply in the
 129 proposed study are the basis of online consumer targeting programs such as Netflix, Google, and
 130 Amazon.com,²⁷ where a service learns automatically how to deliver information that is most relevant to each
 131 user. In the current trial, the RL agent will be a computer system that makes weekly recommendations or
 132 "action choices" for each patient with respect to the mode and intensity of CBT that the patient should receive.
 133 Those recommendations will be based on the patient's progress, the progress of similar patients, and other
 134 contextual information for that action choice.



Potential actions the AI-CBT program will recommend include: a standard 45 minutes telephone CBT therapy session, a 15 minute telephone CBT therapy session, and an IVR automated therapy session designed to teach and reinforce skill-based learning. Fifteen minutes was chosen to be consistent with the time increments of the health and behavior CPT codes (15, 30, 45 and 60) used to bill for behavioral interventions for chronic pain. Content for each session type will be based on standard VA CBT for pain management, modified by a Panel of Experts to be most

143 **Figure 1. The Reinforcement Learning feedback loop.** The AI-CBT actions are the 3 CBT session types; the "reward" is IVR-reported pedometer step-counts, and "state" data is IVR-collected information on patients' CBT skill practice & pain-related functioning.
 144
 145
 146

147 effective given the length and mode of each contact. The AI-CBT agent's recommendation regarding which
 148 action to take will be based on each patient's IVR-reported pedometer step counts (i.e., the "reward") as well
 149 as other "state" information (Figure 1) also collected via IVR. Importantly, the RL algorithm will learn not only
 150 based on each patient's own treatment response, but will incorporate experience from the response of other
 151 patients who have similar characteristics and response trajectories as indicated by the "state space." Based
 152 on this feedback loop, the RL engine will modify the probability distribution across treatment choices and make
 153 recommendations for each patient each week. Because actions will be probabilistic rather than "hard-wired,"
 154 the AI-CBT program will avoid potentially over-reactive treatment changes that can result when therapists
 155 attempt to tailor care non-systematically or using deterministic flow diagrams. AI CBT patients will begin with
 156 an IVR automated therapy session. Based on their progress as measured by feedback on the "reward" and
 157 "state" features, patients who progress toward functional goals will be kept in less resource intensive options,
 158 and patients who need more intensive follow-up will be moved automatically to more time-intensive, therapist-
 159 delivered CBT.
 160

163 Patient Identification and Recruitment

164 Criteria for Opt Out Letters:

165 Patients with diagnoses of chronic back pain receiving care in facilities affiliated with the VA Ann Arbor
166 Healthcare System and the VA Connecticut Healthcare System will be identified via VA Informatics and
167 Computing Infrastructure (VINCI). Eligible patients will have back-pain-related diagnoses including low back
168 and spine conditions, and nerve compression (ICD-9 codes 724.01, 724.02, 724.03, 724.09, 724.1, 724.2,
169 724.3, 724.4 and 724.5 or ICD-10 codes associated with back pain) and a score of ≥ 4 (indicating moderate
170 pain) on the 0-10 Numerical Rating Scale on at least two separate outpatient encounters in the past year.

171 Study Eligibility Criteria:

172 Screening of interested and potentially eligible patients will be conducted by medical record review and
173 telephone interview using validated measures. Inclusion criteria include: (1) at least moderate pain-related
174 disability as determined by a score of 5+ on the Roland Morris Disability Questionnaire at baseline; (2) at least
175 moderate musculoskeletal pain as indicated by a pain score of ≥ 4 on the Numeric Rating Scale; (3) pain on at
176 least half of the days of the prior six months as reported on the Chronic Graded Pain Scale; and (4) a touch-
177 tone cell or land line phone (5) a confirmation of back pain documented in the medical record. Exclusion
178 criteria include: (1) active psychotic symptoms, suicidality, severe depressive symptoms (PHQ-9 score of >20),
179 substance use disorder or dependence, active manic episode or poorly controlled bipolar disorder as identified
180 by Mini International Neuropsychiatric Interview,²⁹ or severe depression identified by chart review of diagnoses
181 and mental health treatment notes; (2) life threatening conditions that could impede participation, such as
182 COPD requiring oxygen or cancer requiring chemotherapy; (3) cognitive impairment defined by a score of ≤ 5
183 on the Six-Item screener;³⁰ (4) sensory deficits that would impair participation in telephone calls; and (5)
184 current CBT or surgical treatment related to back pain (6) Patient does not plan on getting most of medical
185 care for pain in the next year at VA. After obtaining agreement from patients' primary care providers (an email
186 will be sent asking providers if we may send their patients the recruitment letter. Similar to an already approved
187 study, this will be an opt-out email to the providers meaning if they wish for more information we will provide it
188 or if they request their patients do not receive this letter we will not send it. However, we will inform them in the
189 email and at a presentation at a monthly primary care staff meeting that if they do not respond we will assume
190 that we have their permission and send the letter, to the Veterans informing them about the study and inviting
191 participation. Veterans who do not opt-out by postage-paid response card will be called by research staff to
192 explain the study, conduct screening, and solicit their involvement. VA and other investigators have found that
193 this opt-out procedure is less burdensome to patients³¹ and results in a larger sample that is more
194 representative of vulnerable patients³² than opt-in procedures (see Human Subjects). A Waiver or Written
195 Informed Consent (WWIC) will be requested to complete this telephone eligibility screening before informed
196 consent has been signed to join the trial. Willing, eligible Veterans will be given or mailed the consent and
197 HIPAA form along with a postage paid return envelope. We will not begin study procedures until we have
198 received the signed consent and HIPAA forms back. We have used this same process in numerous prior IRB-
199 approved VA studies and have found that it is an efficient and effective way to recruit large samples of
200 Veterans without requiring an in-person recruitment visit. The study coordinator will track the percentage of
201 eligible Veterans who enroll and will actively solicit reasons for declining. This information will be used to
202 assess the intervention's reach as described in the implementation portion of the application (Aim 3).

203 Recruitment methods will include flyers posted in patient care areas and from clinician referrals at the VACHS
204 main campuses (West Haven and Newington) and community-based outpatient clinics (CBOCs), clinician
205 referrals, Craigslist under the "Volunteers" section of the site, flat screen informational televisions around the
206 hospital, Good Morning VA Connecticut, the PRIME Center newsletter, VA Connecticut's Facebook page, a VA
207 public affairs press release, vet centers and numerous locations within the greater New Haven area such as
208 libraries and grocery stores (upon their approval). We will also provide the approved flyer to veteran
209 coordinators at local universities and colleges for posting or distribution. Finally, we will recruit patients at a
210 Pain Education table positioned outside the Patient Education room in Building 2, 1st floor. This table will be
211 staffed by study research staff including research assistants and/or co-investigators. We plan to include
212 approved recruitment flyers and study description cards at the table and information about chronic pain and
213 chronic pain management, pertinent VACHS resources, and other currently approved research studies
214 conducted by our group. Screening of interested and potentially eligible patients will be conducted by medical
215 record review and telephone interview using validated measures as described above, using a WWIC to

complete the eligibility screening measures before Veterans are asked to join the trial. Willing, eligible Veterans will be given or mailed the consent form along with a postage page return envelope in order to enroll in the trial.

Pilot- We will recruit up to 5 participants to pilot the IVR and AI system. These participants will not be included in the final analysis. We will call the pilot participants at approximately week 4 to request feedback about their experiences with the program/system. If we identify any system issues during their participation they will be corrected prior to enrolling patients into the main trial.

Randomization

After completing baseline assessments, patients will be randomized to AI-CBT or standard telephone CBT by the research staff. The randomization sequence and opaque randomization envelopes for recruiters will be generated prior to recruitment by the study statistician using a random number generator. Analysts and the investigators will be blinded to patients' group assignment until initial outcome analyses are completed. To ensure balance across treatment arms in potential modifiers of intervention effect, randomization will be conducted within blocks defined by site (Michigan versus Connecticut).

Common Elements of Standard and AI-CBT

Both CBT conditions will consist of 10 treatment modules delivered over 10 weeks. The same therapist at each site will provide treatment to patients in both groups. In each arm, the 10-week course of therapy will include an introductory module, followed by eight pain coping skills training modules and concluding with a session emphasizing skill consolidation and relapse prevention. The introductory module will present the biopsychosocial model which explains how chronic pain leads to dysfunction and provides a rationale for the efficacy of pain coping skills. The eight skills that will be presented were selected based on their efficacy in improving pain outcomes and their appeal to patients in prior trials. These include sessions on: physical activity, behavioral activation, pacing, sleep hygiene, and relaxation. Other modules will address common maladaptive cognitions including pain catastrophizing and fear of movement or kinesiophobia. Using procedures developed in two previous VA studies, during sessions 2-9 participants will be assigned a goal related to a newly presented skill (e.g., "practice relaxation exercise for 20 minutes daily") and a daily walking goal (e.g., average daily steps over the prior week plus 10%). As participants progress through treatment, they will continue to practice prior goals. In order to maintain consistency in the behavioral and cognitive restructuring targets of CBT between the two treatments, participants in both groups will be assigned the same skill practice goals and the same formula will be used for assigning steps goals.

Patient and Therapist Materials. Patients in both treatment conditions will use a handbook that was developed from materials used in prior trials, refined for use with IVR CBT through an HSR&D-funding Short Term Project Award, and currently in use in our HSR&D-funded IIR of IVR-based CBT for low back pain (see appendices). The handbook is written at the 6th grade reading level so that it can be used with or without the guidance of a therapist. The handbook will be identical for both conditions except that the AI-CBT handbook will contain additional information that describes the three AI modes (45 minute, 15 minute, and IVR sessions) and how to prepare for each type of session. The therapist manuals will be adapted from materials developed for our IVR-based CBT for Chronic Low Back Pain trial. The AI-CBT section will detail specific guidelines for each treatment mode: 45 minute, 15 minute, and IVR.

Pedometers for Monitoring Physical Activity. All patients will be given a pedometer and a log for monitoring their step counts. We will use an Omron HJ-320. Patients will be given or mailed a pedometer after completing their baseline assessment and returning their consent form.

265 **Standard Telephone CBT (control)**

266 Control patients will receive telephone CBT consisting of 10 weekly modules delivered via 45 minute telephone
267 contacts with a therapist. The format of each session will include: (1) review of patients' pedometer logs and
268 coping skill practice, (2) review of previous material and correction of misunderstandings of the information, (3)
269 assignment of new step count goals and discussion of the new skills-based material, and (4) discussion of
270 specific step and skill practice goals. Positive feedback and praise will be offered for any skill practice and step
271 goal efforts and accomplishment. Barriers to practice or goal completion will be identified and problem-solving
272 techniques will be used to address them.

273

274 **Cognitive Behavioral Therapy Supported by Artificial Intelligence (AI-CBT), titled for patients the**
275 *"Responsive Efficient Accessible Chronic pain Technology (REACT) program"*

276 **Daily IVR Reports.** We will collect reports about patients' pedometer-measured step counts, CBT skill
277 practice, and pain-related functioning via daily five-minute IVR calls. If the initial call is missed, the system will
278 automatically try again 15 minutes later and again 1 hour later. We have successfully used these methods in
279 studies achieving high patient response rates. Step counts will measure activity over the prior 24 hours, and
280 patients will report their skill practice using a 0 -10 scale. Pain-related functioning will be assessed using the
281 PEG, a three item scale assessing pain intensity and interference.³³ Practice of target behaviors will be
282 measured using a 0 (not at all accomplished) to 10 (completely accomplished) scale and items that we have
283 successfully used in our ongoing trial if IVR CBT. Questions measured by the telephone IVR system can be
284 seen in the Table 1 below.

285

286 Table 1: IVR Questions

IVR QUESTION FIELDS	
Pain management skill adherence	288
Pain intensity	289
Self efficacy	290
Pain interference	291
Sleep	292
Affect/Mood	293
Meaningful Activity adherence	294
Prior skill practice	295
True/False quiz	296
	297
	298
	299

Step counts will be used in the "reward function" that the RL algorithm will seek to optimize; and functioning and skill practice reports will be used as "state" information (see Appendix A) that the system will take into account when making decisions that optimize patients' treatment course. The AI system will be able to accommodate missing IVR reports, and patients who fail to complete more than 50% of the daily IVR calls in a two week period will be called by a research associate to trouble shoot problems and encourage compliance with feedback. In addition to being the source of data with which AI-CBT will personalize each patient's course of treatment, web-based reports of data from IVR calls will be used to inform therapists of participants' progress. These data will be particularly important for informing the abbreviated 15 minute therapist sessions where a priority will be placed on the efficient use of treatment time, and

300 during the IVR sessions where the entire session will be pre-recorded. Once a week the IVR call will include a
301 brief message alerting patients of the date, time, and modality for their subsequent week's session.

302 **Special Circumstances for Telephone Minutes**

303 Veterans with concerns of telephone minute allotments may have minutes purchased by the study via gift
304 certificates. This will allow these participants to engage in this telephone intervention to the same degree as
305 participants who do not have minute limit concerns. These gift certificates will be distributed in an adhoc basis
306 if a participant presents concerns to study staff. Staff will purchase minutes from the VA canteen with gift
307 certificates and then distribute to participant.

308

309 **AI-CBT Action Recommendations.** After week 1, session options will include: (a) 45 minute live telephone
310 therapist sessions; (b) 15 minute live telephone therapist sessions; and (c) IVR treatment sessions. To avoid
311 scheduling conflicts, AI-CBT patients will be assigned a one-hour block of time each week in which both they
312 and the CBT therapist are available for treatment. This same time slot will be used for either the 45 minute -
313 long therapist sessions, the 15 minute therapist sessions or the IVR CBT sessions. Each Monday morning, the
314 CBT therapists will receive a list of AI-CBT personalized treatment recommendations for that week for each

315 patient. By noon on Monday, the therapist will have a finalized schedule of which patients require what types of
316 contact that week, and which patients need to have a summary of the therapist's comments and
317 recommendations recorded for the week's IVR CBT therapy call.

318 During *Week 1*, AI-CBT patients will look through their handbook and they will review the program's goals and
319 processes, and the standard introductory material contained in session 1 of the standard CBT. At the end of
320 the week the AI-CBT patients will receive a therapist pre-recorded feedback message along with an alert of the
321 date, time and modality of their subsequent week's session. The *45 minute AI-CBT Sessions* will be identical
322 to the control condition and will follow the same progression of content used for control patients. *15 Minute*
323 *Telephone CBT Sessions* will mirror the content of the 45 minute sessions, though in a compressed form. The
324 therapist manual and patient handbook will emphasize the importance of using the session time efficiently and
325 using a consistent format that includes: reviewing the patient's daily IVR reports, clarifying the current week's
326 adaptive pain coping skill in the patient handbook, and setting goals for skill practice and step counts for the
327 coming week. Prior to the session, therapists will review patients' daily IVR reports. If participants have not
328 been successful in meeting step or skill practice goals, the therapist will help the participant address barriers to
329 goal attainment. The therapist then will ask the patient to describe the current week's adaptive pain coping skill
330 as a brief check of their understanding, and will review goals for the coming week with a discussion of
331 anticipated barriers. Remaining time will be used to review the skill and to encourage the patient to read their
332 patient handbook. Much of the content for the IVR CBT sessions has been developed and implemented as part
333 of our ongoing IVR-based CBT for Chronic Low Back Pain trial (see Appendix D). Our experience in that trial
334 suggests that patients complete the IVR sessions more than 90% of the time and that satisfaction rates are
335 high. During these sessions, patient will receive a 2-5 minute pre-recorded feedback message from their
336 therapist, during which the therapist will review the patient's IVR-reported changes in step counts, functioning,
337 and skill practice. Reinforcement will be provided for effort, and improvements will be noted. IVR messages will
338 include a review of the pain coping skill practice and step goals for the coming week, and participants will have
339 the option of leaving a message for their therapist via the IVR system should they have a question. Therapists
340 can leave a response message, also on the IVR system.

341 **The AI Engine.** Patients' IVR-reported step counts, skill practice, and pain-related functioning will be accessed
342 by the AI engine daily to update the probabilities the system uses to determine which treatment to recommend
343 the next week. We will use a state-of-the-art "contextual bandit" AI algorithm (LinUCB) designed to make
344 careful choices while learning quickly from a patient's treatment response as well as the experience of other
345 patients with similar characteristics (see Appendix A for technical details).³⁴⁻³⁷ With increased interactions, the
346 system will learn to tailor decisions more effectively to maximize population-level improvements in functioning
347 while minimizing clinician time. In this way, AI-CBT will function similar to the best clinicians, who learn from
348 experience within and across patients. In the context of the trial, this means that patients enrolled early will
349 likely receive less personalized CBT courses that are relatively similar to the standard CBT approach (i.e., a
350 greater number of 45 minute-long sessions), while patients enrolled later will receive services that are more
351 personalized and include a greater frequency of 15 minute therapist sessions and IVR sessions. To maximize
352 the efficiency of this "learning curve": (1) patients will be recruited over a longer period than would potentially
353 be necessary, so that AI-CBT can gain as much experience as possible from patients recruited first and apply
354 that knowledge to patients entering the program later; and (2) patients will be randomized with a greater "N" in
355 the AI-CBT group in order to maximize the system's experience (see power calculation). As part of our
356 evaluation, we will compare outcomes across randomization groups separately for early versus later enrollees,
357 in order to test the hypothesis that AI-CBT will result in greater efficiency over time. These analyses also will
358 allow us to project program benefits if AI-CBT were implemented in VA for thousands of Veterans and multiple
359 years of experience.

360 **CBT Treatment Fidelity** will be assessed using the Yale Adherence and Competence Scale (YACS),³⁸ a
361 validated scale that assesses therapist adherence and competence in delivering manualized behavioral
362 therapy. A trained rater will rate audiotapes of 30% of all CBT therapist sessions to assure that treatment is
363 consistent with the manual and will provide corrective feedback to the therapists whenever drift occurs.

364 **Role of the Expert Panel.** The AI-CBT program will be supervised with ongoing input from an Expert Panel
365 comprised of experts in: pain management, CBT for chronic pain, clinical trials using behavioral interventions,
366 adaptation of psychotherapy for telephone delivery, and IVR (see Appendix E and letters of support). The
367 Panel will be directed by Dr. Robert Kerns (Co-I) who has led many large and geographically-dispersed panels

of experts in pain research and treatment, and will ensure that the panel meetings are efficient and effective. The Panel will meet regularly by teleconference during the start-up period to review and revise the treatment materials and refine the AI algorithm to reflect any constraints that should be put into place to limit the choices the algorithm can make, e.g., “if the patient’s activity level decreases more than 20% two weeks in a row, recommend two 45 minute-long CBT session regardless of what the prior week’s contact was.” After start-up, the Panel will teleconference quarterly and in ad hoc sessions as needed.

Measurement & Analytic Plan

Overview. We have selected outcome measures based on recommendations from the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) recommendations. Endpoint measures are consistent with CONSORT guidelines recommending that non-inferiority trials use outcomes similar to those used in efficacy studies. In addition to primary and secondary outcomes (defined below), we will examine treatment satisfaction, treatment credibility, patient engagement and dropout, and goal accomplishment. Process and outcome data will be collected via the following sources: *Patient Surveys*: Baseline, three-month, and six-month surveys will be conducted at the VA or via telephone by trained research assistants or via mail, sent with postage paid return envelopes. *Qualitative Interviews*: These will be conducted with purposive samples of patients in the AI-CBT group at follow-up. We will target patients who demonstrate significant improvement, patients who were very satisfied with AI-CBT, patients without significant improvement, patients who were dissatisfied, and patients who dropped out of the intervention. *CBT Therapist Logs*: Logs will be used to track therapist time spent in patient treatment, attempting to reach patients, and key information about those interactions. *IVR*: The AI-CBT IVR system will capture information about intervention patients’ pedometer-measured step-counts, pain related functioning, CBT skill practice, and missed data reporting. *Administrative and Clinical Data Systems*: These will be used to track patients’ use of other VA inpatient and outpatient services for pain management, mental health, and medical care.

Primary Outcome. The 24-item Roland Morris Disability Questionnaire (RMDQ) is an IMMPACT endorsed measure⁴⁰ of pain-related disability for persons with chronic back pain. Strong evidence supports the RMDQ’s reliability, validity, and responsiveness to change during trials.⁴¹

Secondary Outcomes. *Global Pain Intensity* will be assessed using the Numeric Rating Scale (NRS-I) an IMMPACT-recommended 11-point numeric rating scale of pain severity.³⁹ *Pain-Related Interference* will be measured using the Brief Pain Inventory (BPI).⁵⁷ *Pain-related functioning* will be assessed using the PEG, a three item scale assessing pain intensity and interference.³³ *Depression Symptom Severity* will be assessed using the 9-item Patient Health Questionnaire (PHQ-9) a widely used measure with excellent internal consistency and stability.²⁸ *The Patient Global Perception of Change* scale is a single item measure that quantifies a participant’s overall perception of improvement since beginning treatment and the clinical importance of that improvement. Participants indicate improvement on a 7 point “much worse” to “much better” scale. This is a well-validated measure recommended by IMMPACT.⁴⁰ Finally, we will use the *Veterans SF-12 to assess health-related quality of life*. This measure has demonstrated good internal consistency and is strongly correlated with socioeconomic status and morbidities.⁴²

Resource Use (Aim 2). *Intervention Costs.* Therapists will use a log to record time spent in intervention-related activities for a random 20% of all treatment days. Time records will be combined with wage data from the VA Financial Management System to estimate intervention-specific personnel costs. Technology costs of the AI-CBT program include fixed costs (e.g., software development and computer maintenance) plus variable costs (e.g., minute costs for IVR calls). One-time fixed start-up costs will be reported separately. *VA Inpatient and Outpatient Service Use* data will be obtained from the Musculoskeletal Diagnoses Cohort (MSD), a project currently underway as part of the VA Connecticut Healthcare System’s CREATE. The MSD is developing validated algorithms for using VA electronic health record data to identify utilization events, comorbid conditions, receipt of opioid medications, and pain screening results, for patients with pain-related diagnoses. Information on non-VA admissions will be collected by the patient survey. To mitigate recall bias, we will use a two-time frame method that asks about utilization over the past 6 months and over the past 2 months with more weight given to the shorter timeframe.⁴³

420 **Treatment Satisfaction and Engagement (Aim 3).** For patients in the AI-CBT group, we will calculate *IVR*
421 *adherence* as we have in the past,⁴⁴ i.e., as the proportion of days during which an assessment was attempted
422 in which one was successfully completed and the number of weeks during which the patient completed at least
423 four out of seven requested IVR reports. Participants' judgments of *Treatment Credibility* will be assessed
424 using a reliable questionnaire adapted from Borkovec and Nau.⁴⁵ Treatment credibility has been shown to be
425 significantly associated with treatment satisfaction, engagement in treatment, and number of sessions
426 attended. The *Pain Treatment Satisfaction Scale* of the Patient Outcomes Questionnaire will be used to assess
427 patient satisfaction with various domains of pain care.⁴⁶ This 5-item measure shows good internal consistency
428 and significant associations with staff and patient ratings of patient improvement. *Attendance in "Live"*
429 *Telephone CBT Sessions and Program Dropout* In order to understand reasons for treatment dropout, we will
430 attempt to reach samples of patients with low levels of engagement for qualitative interviews. Participants will
431 rate their *Continued Skill Use* at follow-up for each of the target behaviors emphasized in the CBT program on a
432 0 (not at all accomplished) to 10 (completely accomplished) scale. As described above, *Daily IVR calls* will
433 be used to collect data in the AI-CBT condition regarding pedometer measured step-counts, CBT skill practice,
434 and pain-related functioning using pre-recorded questions we have used successfully in our prior studies.

435 **Demographics and Other Covariates Measured at Baseline.** We will measure patients' baseline
436 *Sociodemographic and Pain Characteristics* that have been shown to be associated with treatment outcomes,
437 e.g., age, gender, education level, racial/ethnic background, marital status, occupational status, pain duration,
438 and number and location of pain sites. We also will gather data on participants' level of health literacy.⁴⁷ *Pain*
439 *Classification* will be derived through a systematic evaluation of each enrolled participant's EMR using an
440 assessment tool based on clinical guidelines for diagnosing and treating back pain.⁴⁸ Pain classes will include
441 non-specific back pain, back pain with a radicular component, or back pain associated with other specific
442 spinal causes. A nurse practitioner, who is supported by the West Haven COIN and who has been trained to
443 use this tool and is using it in our trial IIR 09-058. *Psychiatric and Substance Abuse Comorbidities* will be
444 measured using medical record diagnoses and mental health encounters. Additional self-report information will
445 be collected using subscales of the Mini International Neuropsychiatric Interview (MINI)²⁹ related to mood and
446 substance abuse disorders. *Pain Medication Use* will be assessed through patient survey and a review of
447 computerized pharmacy records. Pain medication will be coded as non-steroidal anti-inflammatory, non-
448 narcotic analgesics, narcotic analgesics, and benzodiazepines and other sedative/hypnotics. *Distance from VA*
449 will be calculated and used as a measure of geographic access. The *Pain Catastrophizing Scale* is a 13-item
450 self-report scale that examines thoughts and feelings people may experience when they are in pain including
451 rumination, magnification, and helplessness.⁴⁹ Finally, *Pain-related Fear* will be measured using the Tampa
452 Scale of Kinesiophobia-revised (TSK-R), which has two subscales (Fear of Harm/Activity Avoidance and
453 Pathophysiological Beliefs) and has been shown to be sensitive to treatment-related change.

454 **Sample Size and Power Calculation**

455 Our primary outcome analyses are consistent with the CONSORT Statement on Reporting of Non-inferiority
456 and Equivalence Randomized Trials.⁵⁰ The sample size was calculated using the Non-Inferiority Test module
457 available in the statistical software PASS 2008. To ensure that the AI-CBT program retains a clinically
458 acceptable effect, the non-inferiority margin was set at 2 points on the Roland Morris Disability Questionnaire
459 (RMDQ).⁴¹ A two point difference (or difference in reduction) in the RMDQ is considered to be a minimally
460 clinically significant effect.⁵¹ The power calculation was based on a significance level of 0.025, with a power of
461 90%, when postulating a true difference in group means of 0 and a standard deviation of the outcome of 4.5 in
462 both groups. Specifically, if we denote by D the true difference in mean RMDQ scores (at 12 weeks) between
463 the AI-CBT and standard CBT groups, with the non-inferiority margin set at 2, we plan on testing the null
464 hypothesis $H_0: D \geq 2$ versus the alternative hypothesis $H_1: D < 2$, which amounts to a one-sided, two-sample t-
465 test. Thus, if the null hypothesis is rejected, it can be concluded that AI-CBT is non-inferior to CBT. We will
466 test this hypothesis at a one-sided .025 significance level based on a confidence level where we will reject the
467 null hypothesis when the upper bound of the two-sided 95% confidence interval for D is less than 2. To ensure
468 that the AI-CBT algorithm has as much information as possible to learn quickly how best to tailor patients'
469 course of therapy, we will disproportionately randomize patients to the AI-CBT group in an allocation ratio of
470 1.37:1 for the AI-CBT: standard CBT groups, respectively(of the total sample approximately 60% in the AI-
471 CBT group and 40% in the Standard CBT group). Assuming this ratio, we will have 90% power to detect non-
472 inferiority with a total sample size of 221 patients, or 128:93. To account for a 20% drop-out rate in both
473 groups, we will enroll 278 patients (160 in the AI-CBT group, 118 in CBT group).

474
475 **Baseline Comparability, Reach, and Representativeness.** We will examine baseline differences across
476 groups in measures of study endpoints as well as other potential prognostic indicators, such as patients' age,
477 comorbid diagnoses, and history of pain treatment. Any differences across groups in baseline characteristics
478 will be controlled statistically in analyses comparing outcomes. The RE-AIM framework is a methodology for
479 systematically considering all strengths and weaknesses of an intervention in order to better guide program
480 planning.⁵² To evaluate reach, we will ask patients who decline study participation whether they would be
481 willing to provide informed consent to participate in a brief survey that identifies their reasons for declining
482 participation and the characteristics that differentiate them from enrollees.

483 **Analysis of Endpoints (addressing Specific Aim 1).** We will test for non-inferiority of AI-CBT compared to
484 standard telephone CBT at post treatment by comparing the upper limit of the two-sided 95% confidence
485 interval for the difference in the mean RMDQ scores, calculated as AI-CBT minus standard CBT, to the pre-set
486 non-inferiority margin of 2 points in RMDQ and will conclude that AI-CBT is non-inferior if the upper limit is less
487 than 2. Because intent-to-treat analysis can raise the risk of type I error in a non-inferiority trial,⁵⁰ we will
488 conduct both a per protocol and intent-to-treat analysis. The "per protocol" group assignment will be defined as
489 completing four or more CBT sessions (either IVR or "live" sessions); however, we will revisit this definition with
490 the Expert Panel prior to the start of the trial. We will declare AI-CBT non-inferior to standard CBT only if AI-
491 CBT is shown to be non-inferior using both the intention-to-treat and per-protocol analysis sets. We expect that
492 RMDQ scores will be normally distributed. If not, we will use transformations to achieve normality. We also will
493 develop a two-level linear mixed-effects model that uses RMDQ follow-up scores at both assessment times
494 (three and six months) as the dependent variables; treatment group, time and the treatment by time interaction
495 as categorical explanatory variables; and baseline RMDQ score as a continuous covariate. If this model shows
496 no significant time by group effect, we can drop the interaction term and test for the time-averaged non-
497 inferiority of AI-CBT compared to standard CBT between 3 and 6 months. This model will also allow for
498 adjustment for design-related factors (e.g., site and age). An unstructured variance-covariance matrix will be
499 used to model the error variance. Secondary outcomes including pain intensity, emotional functioning, global
500 perception of change, and quality of life will be analyzed in a manner similar to that used for the primary
501 outcome. Analyses of all other outcomes will be conducted on an intent-to-treat basis.

502 **Intensity of Service Use (Specific Aim 2).** We will compare service utilization by category (e.g., CBT
503 therapist time, PCP visits, and pharmacy use) between groups. We will conduct a budget impact analysis⁵³ and
504 will include the cost of the intervention (personnel, supplies, CBT therapist training, and IVR fixed/variable
505 costs) as well as costs for specific medical care services likely to be affected. Data from CBT therapists time
506 records will be combined with wage data from the VA Financial Management System to produce estimates of
507 intervention-specific personnel costs. Costs associated with the use of specific medical care services, such as
508 medications, will be obtained from the Decision Support System (DSS) files. Cost analysis will be conducted in
509 accordance with the guidance provided by Mauskopf et al.⁵³ including the use of sensitivity analysis and
510 scenarios that allow for varying assumptions about intervention uptake, compliance or component costs. All
511 resource use and cost comparisons will be adjusted for any observed differences in baseline
512 characteristics. Because costs of resource utilization are usually skewed, alternative modeling techniques
513 (e.g., log-transformed costs, negative binomial regression) will be used.

514 **Intervention Engagement and Satisfaction with Care (Specific Aim 3).** We will conduct extensive analyses
515 of the process of intervention delivery in both arms. We will monitor the proportion of telephone CBT sessions
516 that are completed, and we will determine the patient and session characteristics associated with patients'
517 reports of skill practice. Patients in the AI-CBT group will report their satisfaction with aspects of the
518 intervention (e.g., whether it provided information useful for achieving behavioral targets), and we will assess
519 the correlation between satisfaction ratings and measures of: intervention engagement, patients' baseline
520 characteristics, and changes in pain-related functioning. Differential dropout across groups will be examined
521 using Kaplan-Meier curves and survival models.

522 **Preplanned Subgroup Analysis.** Because AI-CBT will continue to learn patterns in patients' experience
523 throughout the intervention period, we hypothesize that the second 50% of patients randomized will show an
524 even larger difference in clinician time than the first 50%, while still demonstrating non-inferiority in pain-related
525 outcomes. Differences in pain related functioning and in clinician treatment time across treatment groups will
526 be tested in this subgroup analysis after stratifying the sample into early versus later recruits.

527 **Approach to Missing Data.** If more than 15% of a covariate is missing, we will use multiple imputation
528 methods based on the SAS MI Procedure. We will check if the pattern of missingness is monotonic (i.e., if
529 patients missing data at 3 months also have missing data at 6 months) and use a Markov chain Monte Carlo
530 method that assumes multivariate normality to impute missing values. We will impute five sets of data and
531 combine the imputed results using the SAS MIANALYZE procedure to obtain a valid estimate of the confidence
532 limit and treatment effect.⁵⁴ When data are missing for items within scale scores, we will use recommended
533 imputation procedures rather than deleting patients list-wise from the analysis.

534 **Mediators and Moderators of Intervention Effects.** We will use multivariate modeling to identify the
535 mechanisms through which the intervention achieves effects on outcomes and differential effects across
536 subgroups.⁵⁵ Initial models will include only treatment group as the predictor. Subsequent nested models will
537 introduce potential mediators (such as the number of completed therapist sessions), and we will evaluate
538 changes in the relationship between experimental condition and outcomes before and after covariates are
539 introduced. Analyses of effect moderation will focus on baseline pain severity and comorbid diagnoses using
540 standard approaches to evaluate interactions between these covariates and patients' experimental condition.⁵⁵
541 Significant interactions will be interpreted by plotting regression lines for predicted outcomes of patients with
542 high and low values of the moderator.

543 **Evaluating the Reliability of Patients' IVR Reports.** We will evaluate the integrity of IVR-reported step
544 counts and functioning by examining associations between IVR reports and baseline characteristics that the
545 literature suggests would be associated with patients' functioning (e.g., baseline SF-12 scores, comorbid
546 medical diagnoses, and age). We also will examine serial correlations across IVR reports under the
547 assumption that all correlations between scores and proximal scores should be positive and roughly of equal
548 magnitude controlling for the time difference between reports.

549 **RE-AIM⁵³ Dimensions of Intervention Adoption, Implementation, and Maintenance.** Adoption will be
550 evaluated by examining variation in study participation and intervention engagement across sociodemographic
551 and clinical subgroups of eligible patients. For example, we will determine whether older patients or those with
552 less education have more difficulty responding to queries about their step counts or pain-related functioning via
553 IVR. Adoption at the provider level will be monitored by recording the proportion of providers who are willing to
554 have their patients participate and providers' reasons for not participating. Implementation and maintenance
555 will be evaluated through semi-structured questions at follow-up designed to identify program characteristics
556 that might be a barrier to patients' use of the intervention in other settings and the intervention characteristics
557 that patients feel would make it more valuable to others with chronic pain. We also will meet with clinicians in
558 each site to gauge their willingness to adopt and maintain a similar intervention, and the ways such a system
559 can be designed to best complement existing services.

560 **Qualitative Interviews and Mixed-Methods.** We will use audio-taped interviews with patients, CBT therapists
561 and/or team members to provide a context for interpreting intervention effects and suggest additional
562 subgroup analyses. Interviews will be transcribed verbatim, and we will enter the transcripts into NVivo for file
563 storage and selective retrieval. Using accepted techniques,⁵⁶ Drs. Piette and Heapy will independently read
564 transcripts, approaching the data with analytic categories in mind, but identifying other categories in the data.
565 An iterative process will be used until agreement is reached on categories and their definitions, after which we
566 will develop a coding template and enter it into NVivo as a tree diagram.

567 568 **6. References**

- 570 1. Johannes CB, Le TK, Zhou X, Johnston JA, Dworkin RH. The Prevalence of Chronic Pain in United
571 States Adults: Results of an Internet-Based Survey. *J Pain*. 2010;11:1230-1239.
- 572 2. Crowe M, Whitehead L, Jo Gagan M, Baxter D, Panckhurst A. Self-management and chronic low back
573 pain: a qualitative study. *J AdvNurs*. 2010;66:1478-1486.
- 574 3. Walker, Robyn L. U.S. War Veterans and Pain. painedu.org . 2012.
- 575 4. Kerns RD, Philip EJ, Lee AW, Rosenberger PH. Implementation of the Veterans Health Administration
576 National Pain Management Strategy. *Translational Behav Med*. 2011.
- 577 5. Spelman J, Hunt S, Seal K, Burgo-Black A. Post Deployment Care for Returning Combat Veterans. *J*
578 *Gen Intern Med*. 2012;27:1200-1209.

- 579 6. Buckenmaier, CC and Gallagher, RM. War on Pain: New Strategies in Pain Management for Military
580 Personnel and Veterans. 2011. Federal Practitioner Supplement.
- 581 7. Lew HL, Otis JD, Tun C, Kerns RD, Clark ME, Cifu DX. Prevalence of chronic pain, posttraumatic stress
582 disorder, and persistent postconcussive symptoms in OIF/OEF veterans: Polytrauma clinical triad. *J*
583 *Rehabil Res Dev.* 2009;46:697-702.
- 584 8. Girona RJ, Clark ME, Ruff RL et al. Traumatic brain injury, polytrauma, and pain: Challenges and
585 treatment strategies for the polytrauma rehabilitation. *Rehabil Psychol.* 2009;54:247-258
- 586 9. Kerns, R. D. Pain among returning service members from OEF/OIF. 2007.
- 587 10. Chou R, Huffman LH. Nonpharmacologic Therapies for Acute and Chronic Low Back Pain: A Review of
588 the Evidence for an American Pain Society/American College of Physicians Clinical Practice Guideline.
589 *Ann Intern Med.* 2007;147:492-504.
- 590 11. Manchikanti L, Singh V, Datta S, Cohen SP, Hirsch JA. Comprehensive review of epidemiology, scope,
591 and impact of spinal pain. *Pain physician.* 2009;12:E35.
- 592 12. Nicholas MK, Asghari A, Corbett M et al. Is adherence to pain self-management strategies associated
593 with improved pain, depression and disability in those with disabling chronic pain? *Eur J Pain.* 2011.
- 594 13. Dobscha SK, Corson K, Perrin NA et al. Collaborative Care for Chronic Pain in Primary Care. *JAMA.*
595 2009;301:1242-1252.
- 596 14. Sauro, Measuring Usability with the System Usability Scale (SUS) (2011)
597 <http://www.measuringusability.com/sus.php>
- 598 15. Kroenke K, Bair MJ, Damush TM et al. Optimized Antidepressant Therapy and Pain Self-management in
599 Primary Care Patients With Depression and Musculoskeletal Pain. *JAMA.* 2009;301:2099-2110.
- 600 16. Manchikanti L, Singh V, Datta S, Cohen SP, Hirsch JA. Comprehensive review of epidemiology, scope,
601 and impact of spinal pain. *Pain Physician.* 2009;12:E35.
- 602 17. Institute of Medicine. Relieving Pain in America: A Blueprint for Transforming Prevention, Care,
603 Education, and Research. 2011. Institute of Medicine.
- 604 18. Lamb SE, Hansen Z, Lall R et al. Group cognitive behavioural treatment for low-back pain in primary
605 care: a randomised controlled trial and cost-effectiveness analysis. *The Lancet.* 2010;375:916-923.
- 606 19. Smeets RJEM, Vlaeyen JWS, Hidding A, Kester ADM, van der Heijden GJMG, Knottnerus JA. Chronic
607 low back pain: Physical training, graded activity with problem solving training, or both? The one-year
608 post-treatment results of a randomized controlled trial. *Pain.* 2008;134:263-276.
- 609 20. Williams DA, Kuper D, Segar M, Mohan N, Sheth M, Clauw DJ. Internet-enhanced management of
610 fibromyalgia: A randomized controlled trial. *Pain.* 2010;151:694-702.
- 611 21. Kerns RD, Rosenberg R, Jamison RN, Caudill MA, Haythornthwaite J. Readiness to adopt a self-
612 management approach to chronic pain: the Pain Stages of Change Questionnaire (PSOCQ). *Pain.*
613 1997;72:227-234.
- 614 22. Gersh E, Arnold C, Gibson SJ. The Relationship Between the Readiness for Change and Clinical
615 Outcomes in Response to Multidisciplinary Pain Management. *Pain Medicine.* 2011;12:165-172.
- 616 23. Kerns RD, Rosenberg R. Predicting responses to self-management treatments for chronic pain:
617 application of the pain stages of change model. *Pain.* 2000;84:49.
- 618 24. Jensen MP, Nielson WR, Kerns RD. Toward the development of a motivational model of pain self-
619 management. *J Pain.* 2003;4:477-492.
- 620 25. Biller N, Arnstein P, Caudill MA, Federman CW, Guberman C. Predicting completion of a cognitive-
621 behavioral pain management program by initial measures of a chronic pain patient's readiness for
622 change. *Clin J Pain.* 2000;16:352-359.
- 623 26. Keefe FJ. Cognitive behavioral therapy for managing pain. *The Clinical Psychologist* 1996;49:4-5.
- 624 27. Lihong L, Chu W, Langford J, Schapire RE. A contextual bandit approach to personalized news article
625 recommendation. *WWW* 2010:661-70.
- 626 28. Kroenke, K. & Spitzer, R. (2002). The PHQ-9: A New Depression Diagnostic and Severity
627 Measure. *Psychiatric Annals*, 39(9),1-7.
- 628 29. Sheehan DV, Lecrubier Y, Harnett-Sheehan K, et al. The Mini International Neuropsychiatric Interview
629 (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview. *Journal of*
630 *Clinical Psychiatry* 1998;59:22-33.
- 631 30. Tariq SH, Tumosa, Chibnall JT, Perry MH, Morley JE. Comparison of the Saint Louis University mental
632 status examination and the Mini Mental state examination for detecting dementia and mild
633 neurocognitive disorder - a pilot study. *American Journal of Geriatric Psychiatry* 2006;14:900-10.

- 634 31. Singleton P, Wadsworth M. Consent for the use of personal medical data in research. *BMJ*
635 2006;333:255-8.
- 636 32. Junghans C, Feder G, Hemingway H, Timmis A, Jones M. Recruiting patients to medical research:
637 double blind randomised trial of "opt-in" versus "opt-out" strategies. *BMJ Online* 2005;331:940+.
- 638 33. [Krebs EE](#), [Lorenz KA](#), [Bair MJ](#), [Damush TM](#), [Wu J](#), [Sutherland JM](#), [Asch SM](#), [Kroenke K](#). Development and initial
639 validation of the PEG, a three-item scale assessing pain intensity and interference. *J Gen Intern Med*. 2009; 6:733-
640 8.
- 641 34. Li L, Chu W, Langford J, Schapire RE. A contextual-bandit approach to personalized news article
642 recommendation. *WWW 2010*;Apr 26-30:661-70.
- 643 35. Abbasi-Yadkori Y, Pal D, Szepesvari C. Improved algorithms for linear stochastic bandits. In *Advances*
644 *in Neural Information Processing Systems (NIPS)*. 2011.
- 645 36. Chu W, Li L, Reyzin L, Schapire RE. Contextual bandits with linear payoff functions. In *International*
646 *Conference on Artificial Intelligence and Statistics* Available at:
647 http://machinelearningwustledu/mlpapers/paper_files/AISTATS2011_ChulRS11pdf 2011:208-14.
- 648 37. Auer P. Using confidence bounds for exploitation-exploration trade-offs. *Journal of Machine Learning*
649 *Research* 2002;3:397-422.
- 650 38. Carroll KM, Nich C, Silfry RL, et al. A general system for evaluating therapist adherence and
651 competence in psychotherapy research in the addictions. *Drug and Alcohol Dependence* 2000;57:225-
652 38.
- 653 39. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in
654 chronic pain clinical trials: IMMPACT recommendations. *The Journal of Pain* 2008;9:105-21.
- 655 40. Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMMPACT
656 recommendations. *Pain* 2005;1:9-19.
- 657 41. Roland M, Fairbank J. The Roland-Morris Disability Questionnaire and the Oswestry Disability
658 Questionnaire. *Spine* 2000;25:115-24.
- 659 42. Kazis LE, Lee A, Spiro A, et al. Measurement comparisons of the medical outcomes study and veterans
660 SF-36® health survey. *Health Care Financing Review* 2004;25:43.
- 661 43. Bhandari A, Wagner T. Self-reported utilization of health care services: improving measurement and
662 accuracy. *Medical Care Research and Review* 2006;63:217-35.
- 663 44. Piette JD, Rosland AM, Marinec NS, Striplin D, Bernstein SJ, Silveira MJ. Engagement with automated
664 patient monitoring and self-management support calls: experience with a thousand chronically-ill
665 patients. *Medical care* 2013;51:216-23. PMID: 23222527.
- 666 45. Borovec TD, Nau CD. Credibility of analog therapy rationales. *Experimental Psychology* 1972;3:257-69.
- 667 46. Clark ME, Gironda RJ, Young RW. Development and validation of the Pain Outcomes Questionnaire-
668 VA. *Journal of Rehabilitation Research and Development* 2003;40:381-96.
- 669 47. Chew LD, Bradley KA, Boyko E, J. Brief questions to identify patients with inadequate health literacy.
670 *Family Medicine* 2004;36:588-94.
- 671 48. Chou R, Qaseem A, Snow V, et al. Diagnosis and treatment of low back pain: a joint clinical practice
672 guideline from the American College of Physicians and the American Pain Society. *Ann Intern Med*
673 2007;147:478-91.
- 674 49. Sullivan MJL, Bishop S, Pivik J. The pain catastrophizing scale: development and validation.
675 *Psychological Assessment* 1995;7:524-32.
- 676 50. Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJW. Reporting of noninferiority and
677 equivalence trials: an extension of the CONSORT statement. *JAMA* 2006;295:1152-60.
- 678 51. Bombardier M, Hayden J, Beaton DE. Minimal clinical importance difference: low back pain outcome
679 measures. *Rheumatology* 2001;28:431-8.
- 680 52. Glasgow RE, McKay HG, Piette JD, Reynolds KD. The RE-AIM framework for evaluating interventions:
681 what can it tell us about approaches to chronic illness management? *Patient Educ Couns* 2001;44:119-
682 27.
- 683 53. Mauskopf JA, Sullivan SD, Annemans L. Principles of good practice for budget impact analysis: report of
684 the ISPOR Task Force on good research practices--budget impact analysis. *Value Health* 2007;10:336-
685 47.
- 686 54. Rubin DB. Multiple imputation after 18+ years (with discussion). Rubin, DB (1996) Multiple imputation
687 after 18+ years (with discussion) *Journal of the American Statistical Association*, 91, 473-489
688 1996;91:473-89.

689
690
691
692
693
694

55. Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. *J Pers Soc Psychol* 1986;51:1173-82.
56. Miller W, Crabtree B. Clinical research: a multimethod typology and qualitative roadmap. In: Crabtree B, Miller, WL, ed. *Doing qualitative research*. Thousand Oaks: Sage Publications; 1999.
57. Keller et. al, (2004). Validity of the Brief Pain Inventory for Use in Documenting the Outcomes of Patients With Noncancer Pain. *Clinical Journal of Pain*, 20(5), 309-318.